Suppr超能文献

一例异环磷酰胺引起的急性肾损伤、范可尼综合征和肾性尿崩症。

A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus.

机构信息

Saint Louis University School of Medicine, 1008 S. Spring Ave., St. Louis, MO, 63110, USA.

出版信息

CEN Case Rep. 2024 Jun;13(3):194-198. doi: 10.1007/s13730-023-00829-z. Epub 2023 Oct 28.

Abstract

Ifosfamide, a cytotoxic antineoplastic drug, can induce rare complications of Fanconi syndrome and nephrogenic diabetes insipidus (DI). Ifosfamide-induced Fanconi syndrome tends to occur in patients with certain risk factors including young age, high cumulative ifosfamide dose, and coadministration of cisplatin. Nephrogenic DI causes polyuria from impaired urinary concentrating ability due to resistance to arginine vasopressin (AVP) at the collecting duct. These complications are serious and potentially fatal. Here, we describe a case of a middle-aged man without risk factors who was admitted for the management of acute kidney injury and electrolyte derangements after his fourth cycle of chemotherapy including ifosfamide for synovial sarcoma. He was found to have hypokalemia, hypophosphatemia, renal glycosuria, and aminoaciduria, likely from Fanconi syndrome, which were managed by electrolyte replacement therapy. In addition, polyuria and hypernatremia were considered due to nephrogenic DI, which partially responded to desmopressin treatment. This case highlights the importance of the routine electrolytes monitoring after ifosfamide treatment.

摘要

异环磷酰胺是一种细胞毒性抗肿瘤药物,可引起范可尼综合征和肾性尿崩症(DI)等罕见并发症。异环磷酰胺引起的范可尼综合征往往发生在具有某些危险因素的患者中,包括年轻、累积异环磷酰胺剂量高以及与顺铂合用。肾性尿崩症导致多尿,由于集合管对精氨酸加压素(AVP)的抵抗导致尿浓缩能力受损。这些并发症很严重,可能致命。在这里,我们描述了一例无危险因素的中年男性,他在接受第四个周期化疗后因急性肾损伤和电解质紊乱入院,化疗药物包括异环磷酰胺治疗滑膜肉瘤。他被发现低钾血症、低磷血症、肾性糖尿和氨基酸尿,可能是范可尼综合征,通过电解质替代疗法进行治疗。此外,多尿和高钠血症被认为是由于肾性尿崩症引起的,部分对去氨加压素治疗有反应。本例强调了异环磷酰胺治疗后常规电解质监测的重要性。

相似文献

1
A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus.
CEN Case Rep. 2024 Jun;13(3):194-198. doi: 10.1007/s13730-023-00829-z. Epub 2023 Oct 28.
2
Ifosfamide-induced Fanconi syndrome and desmopressin-responsive nephrogenic diabetes insipidus.
Am J Med. 2013 Jul;126(7):e7-8. doi: 10.1016/j.amjmed.2013.02.005. Epub 2013 May 16.
3
Ifosfamide-induced nephrogenic diabetes insipidus responsive to supraphysiologic doses of intravenous desmopressin.
Clin Nephrol Case Stud. 2021 Jul 1;9:87-92. doi: 10.5414/CNCS110589. eCollection 2021.
4
Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
Korean J Intern Med. 2014 Mar;29(2):246-9. doi: 10.3904/kjim.2014.29.2.246. Epub 2014 Feb 27.
5
Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient.
Nephrol Dial Transplant. 1998 Jun;13(6):1547-9. doi: 10.1093/ndt/13.6.1547.
7
Fanconi's syndrome and nephrogenic diabetes insipidus in an adult treated with ifosfamide.
Pharmacotherapy. 2012 Jan;32(1):e12-6. doi: 10.1002/PHAR.1013.
8
Ifosfamide-induced nephrogenic diabetes insipidus and Fanconi syndrome in a patient with femur osteosarcoma.
Caspian J Intern Med. 2024 Sep 7;15(4):743-747. doi: 10.22088/cjim.15.4.743. eCollection 2024 Fall.
9
Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.
Am J Kidney Dis. 2017 Feb;69(2):317-319. doi: 10.1053/j.ajkd.2016.07.037. Epub 2016 Oct 22.
10
Hypokalemia Induced Partial Nephrogenic Diabetes Insipidus: A Case Report.
JNMA J Nepal Med Assoc. 2024 Feb 29;62(271):217-219. doi: 10.31729/jnma.8501.

引用本文的文献

1
Ifosfamide-Induced Partial Arginine Vasopressin Resistance Responsive to Vasopressin/Desmopressin and Amiloride.
Cureus. 2025 May 11;17(5):e83897. doi: 10.7759/cureus.83897. eCollection 2025 May.
2
Managing Ifosfamide-Induced Arginine Vasopressin Resistance: Diagnostic and Treatment Strategies.
Cureus. 2025 Mar 26;17(3):e81236. doi: 10.7759/cureus.81236. eCollection 2025 Mar.

本文引用的文献

1
Tumor-induced Osteomalacia: A Comprehensive Review.
Endocr Rev. 2023 Mar 4;44(2):323-353. doi: 10.1210/endrev/bnac026.
2
Ifosfamide-induced nephrogenic diabetes insipidus responsive to supraphysiologic doses of intravenous desmopressin.
Clin Nephrol Case Stud. 2021 Jul 1;9:87-92. doi: 10.5414/CNCS110589. eCollection 2021.
3
The growing pains of ifosfamide.
Clin Kidney J. 2020 Apr 17;13(4):500-503. doi: 10.1093/ckj/sfaa017. eCollection 2020 Aug.
4
Proximal renal tubular acidosis with and without Fanconi syndrome.
Kidney Res Clin Pract. 2019 Sep 30;38(3):267-281. doi: 10.23876/j.krcp.19.056.
5
Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.
Nat Rev Nephrol. 2015 Oct;11(10):576-88. doi: 10.1038/nrneph.2015.89. Epub 2015 Jun 16.
6
Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
Korean J Intern Med. 2014 Mar;29(2):246-9. doi: 10.3904/kjim.2014.29.2.246. Epub 2014 Feb 27.
7
Ifosfamide-induced Fanconi syndrome and desmopressin-responsive nephrogenic diabetes insipidus.
Am J Med. 2013 Jul;126(7):e7-8. doi: 10.1016/j.amjmed.2013.02.005. Epub 2013 May 16.
8
Fanconi's syndrome and nephrogenic diabetes insipidus in an adult treated with ifosfamide.
Pharmacotherapy. 2012 Jan;32(1):e12-6. doi: 10.1002/PHAR.1013.
10
Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule.
Arch Toxicol. 2008 Sep;82(9):607-14. doi: 10.1007/s00204-007-0275-5. Epub 2008 Jan 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验